Torres, A;
Niederman, M. S;
Chastre, J;
Ewig, S;
Fernandez-Vandellos, P;
Hanberger, H;
Kollef, M;
Li Bassi, G;
Luna, C. M;
Martin-Loeches, I;
Paiva, J. A;
Read, R. C;
Rigau, D;
Timsit, J. F;
Welte, T;
Wunderink, R.
The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP and VAP have been conducted and new information has become available. Studi...
Wedzicha, JA;
Calverley, PMA;
Albert, RK;
Anzueto, A;
Criner, GJ;
Hurst, JR;
Miravitlles, M;
Papi, A;
Rabe, KF;
Rigau, D;
Sliwinski, P;
Tonia, T;
Vestbo, J;
Wilson, KC;
Krishnan, JA.
This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.Comprehensive evidence syntheses were performed to summarise al...
Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico,
Aminopiridinas/uso terapéutico,
Benzamidas/uso terapéutico,
Ciclopropanos/uso terapéutico,
Fluoroquinolonas/uso terapéutico,
Macrólidos/uso terapéutico,
Antagonistas Muscarínicos/uso terapéutico,
Inhibidores de Fosfodiesterasa 4/uso terapéutico,
Progresión de la Enfermedad,
Enfermedad Pulmonar Obstructiva Crónica,
Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico,
Enfermedad Pulmonar Obstructiva Crónica/fisiopatología,
Prevención Secundaria/normas,
Agonistas de Receptores Adrenérgicos beta 2,
Aminopiridinas,
Benzamidas,
Ciclopropanos,
Fluoroquinolonas,
Macrólidos,
Antagonistas Muscarínicos,
Inhibidores de Fosfodiesterasa 4
Miravitlles, M;
Soler-Cataluña, J. J;
Calle, M;
Molina, J;
Almagro, P;
Quintano, J. A;
Trigueros, J. A;
Cosío, B. G;
Casanova, C;
Antonio Riesco, J;
Simonet, P;
Rigau, D;
Soriano, J. B;
Ancochea, J.
La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el fenotipo. La Guía española de la EPOC (GesEPOC) estableció por primera vez en 2012 unas pautas de tratamiento farmacológico bas...
Lucas, JS;
Barbato, A;
Collins, SA;
Goutaki, M;
Behan, L;
Caudri, D;
Dell, S;
Eber, E;
Escudier, E;
Hirst, RA;
Hogg, C;
Jorissen, M;
Latzin, P;
Legendre, M;
Leigh, MW;
Midulla, F;
Nielsen, KG;
Omran, H;
Papon, JF;
Pohunek, P;
Redfern, B;
Rigau, D;
Rindlisbacher, B;
Santamaria, F;
Shoemark, A;
Snijders, D;
Tonia, T;
Titieni, A;
Walker, WT;
Werner, C;
Bush, A;
Kuehni, CE.
The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex and expensive, tests. In many cases, however, the diagnosis remains difficult despite the array of sophisticated diagnostic tests. There is no "gold standard" reference test. Hence, a Task Force supported by the ...
